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The Tox21 program initiated a shift in toxicology toward in vitro testing with a focus on 
the biological mechanisms responsible for toxicological response. We discuss the appli-
cations of these initiatives to developmental toxicology. Specifically, we briefly review 
current approaches that are widely used in developmental toxicology to demonstrate 
the gap in relevance to human populations. An important aspect of human relevance 
is the wide variability of cellular responses to toxicants. We discuss how this gap can 
be addressed by using cells isolated from umbilical cord blood, an entirely non-invasive 
source of fetal/newborn cells. Extension of toxicological testing to collections of human 
fetal/newborn cells would be useful for better understanding the effect of toxicants on 
fetal development in human populations. By presenting this perspective, we aim to initi-
ate a discussion about the use of cord blood donor-specific cells to capture the variability 
of cellular toxicological responses during this vulnerable stage of human development.
Keywords: developmental toxicity, cord blood cells, in vitro models, risk assessment, individual variability, high-
throughput testing, endothelial progenitor cells, endothelial colony-forming cells
iNTRODUCTiON
Blood from umbilical cord (cord blood) has been recognized as a source of hematopoietic cells 
useful for transplantation to patients with malignant or genetic diseases (1). At the same time, cord 
blood is a source of a fetal/newborn material that is being obtained in an entirely non-invasive 
way. Cord blood contains stem and progenitor cells, which are possible to isolate, expand in vitro, 
and cryopreserve. A library of cord blood-derived stem/progenitor cells can represent at a cellular 
level a population of newborns. Such a library could be a powerful tool to study the variability of 
human fetal responses to a wide variety of developmental toxicants. Studying individual variability is 
rooted in an epidemiological approach that is not currently incorporated into standard toxicological 
testing. Use of cord blood cells allows for direct toxicological testing in the most vulnerable human 
populations (i.e., human fetuses and newborns), and thus, overcomes limitations associated with 
traditional in vivo and in vitro test methods.
USe OF ANiMAL MODeLS iN PReDiCTiON OF HUMAN 
ReSPONSeS TO eNviRONMeNTAL HAZARDS
Developmental toxicology focuses on predicting the ability of environmental hazards to cause 
anatomical and functional birth defects in humans (2). Currently, developmental toxicology 
depends on studies employing in vivo animal models supported by data derived from molecular 
and cell-based models (3, 4); the in  vivo models employ pregnant animals, primarily, rats, and 
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rabbits (3). Such models allow observing pharmacokinetics and 
pharmacodynamics with the main outcome being an incidence 
of malformations. This information provides the main basis for 
public health decisions regarding safe levels of exposure to drugs 
and toxicants, including pesticides and industrial chemicals 
(3, 5). Specifically, the Food and Drug Administration (FDA) 
according to the International Conference on Harmonization 
(ICH) S5(R2) document mandates new pharmaceutical agents to 
be tested for developmental toxicity in two animal species (6, 7). 
The assumptions used in regulatory practice consider humans as 
more sensitive than animals; if a compound is developmentally 
toxic in animals, it is assumed to be toxic in humans at blood 
levels that are within 20-fold of the therapeutic blood level (5). 
The high cost and inefficiency of the in vivo animal testing have 
been recognized; these limitations can be partially mitigated by 
using appropriate in vitro models (8–13).
Widely accepted today, in vitro testing includes the embryonic 
stem cell test for embryotoxicity, the micromass embryotoxicity 
assay, and the whole rat embryo embryotoxicity assay (8–13). 
These test methods are used to assess the toxicity of a substance 
or side effects of a drug on embryonic cells while avoiding 
the influence of maternal toxicity (14). The embryonic stem 
cell test is performed using a mouse embryonic stem cell line 
(mESC) and differentiated 3T3 fibroblasts. Inhibition of mESC 
differentiation into cardiomyocytes serves as an indicator of 
developmental toxicity, while increased cytotoxicity in mESC 
vs. fibroblasts provides information on the specificity of toxic-
ity to embryonic development. The micromass embryotoxicity 
assay utilizes embryonic cells isolated from a rat embryo. Most 
frequently, this assay uses cells from developing limb buds or 
midbrain to approximate how compounds influence organ 
growth over a limited time period of embryonic development. 
The whole rat embryo assay assesses signs of malformation or 
retardation in cultured whole embryos. A combination of these 
approaches was used to test 20 therapeutic drugs, 16 of them were 
contraindicated in pregnancy and 4 drugs that were considered 
to be safe (15). This study used P19C5 mouse embryoid cells and 
NIH/3T3 fibroblasts (15). P19C5 mouse embryoid cells exhibit 
axial elongation morphogenesis in vitro and, therefore, were used 
not only as a cellular representation of an embryo but also as a 
model of embryonic growth, differentiation, and morphogen-
esis. The tested drugs presented a wide spectrum of therapeutic 
targets and chemical properties, including acitretin (treats skin 
diseases), diethylstilbestrol (prevents miscarriages and premature 
deliveries), doxylamine (anti-histamine for allergies), lovastatin 
(reduces LDL cholesterol), and others. This study showed a strong 
correlation between the in vitro observed effects and the expected 
developmental toxicity of the drugs (15). Thus, the described 
approaches cover a variety of toxicological effects from cellular 
toxicity to organ formation and growth retardation.
The unique challenge to studying developmental toxicology in 
mammals (including humans) is the lack of accessibility to the 
developing fetus. This is addressed to a limited extent by non-
mammalian animal models that use amphibians, avians, or fish 
and allow direct observation of how different concentrations of a 
compound influence embryonic development. The major advan-
tage of these models is the ability to observe toxicological effects 
on spatial and temporal development of the whole animal. For 
example, amphibian metamorphosis depends on thyroid hormone 
function along the hypothalamic–pituitary–thyroid axis (16). The 
amphibian tadpole bioassay evaluates a number of morphological 
endpoints, including thyroid gland histopathology, hind limb and 
snout-vent length, and wet body weight. The molecular aspect of 
this assay identifies disruption of thyroid function, including per-
turbations in thyroid hormone synthesis, transport, and metabo-
lism by environmental contaminants (16). Widely recognized 
and included in the Organization for Economic Co-operation 
and Development (OECD) and the Environmental Protection 
Agency (EPA) guidelines, African clawed frog (Xenopus laevis) 
metamorphosis is being used for screening potential endocrine 
disruptors (17). The new sub-specialties using whole organisms 
include functional toxicology or toxicogenomics based on the 
models with defined genetic background; such models allow for 
assessing the role of specific gene products in tolerance to chemi-
cals during embryonic development (18). Specifically, organisms 
harboring gene deletions or depleted proteins are used to exam-
ine genetic requirements for toxicity tolerance. In this regard, 
zebrafish is a highly promising model offering several advantages. 
A transparent chorion and embryo allow for direct observation 
of morphological development. Furthermore, these observations 
can be connected to a complex behavior in the adult zebrafish 
due to a short maturation period, which provides a window to 
developmental neurobehavioral testing (19). Together, these tests 
provide valuable information on how toxic a specific compound 
can be to embryonic development.
To what extent are these models applicable to human embry-
onic and fetal development? This question remains one of the 
major challenges of current developmental toxicological testing. 
It appears that a fundamental gap between animal – both in vivo 
and in vitro – models and an assessment of human health risks 
lies in the fact that developmental responses to compounds are 
influenced by the reproductive strategies of the species (20). Short-
lived species with rapid reproduction and long-lived species with 
few offspring and delayed maturation represent two extremes. In 
that respect, short-lived rodents can model human development 
only to a limited extent (21). Non-mammalian models are likely to 
be even less relevant to human development. We contend that this 
gap in whole organism models can be breached by using in vitro 
data. Taking into account that fundamental cellular responses 
are conserved across the species, in vitro embryotoxicity models 
remain an important research tool, and can become part of regula-
tory decisions, given that the results are supported by the available 
human data. In this context, utilizing cord blood cells may prove 
to be valuable in advancing the assessment of developmental toxi-
cological effects as the cells are obtained from the umbilical cord 
of a human at the boundary of fetal and newborn development.
CORD BLOOD AS A SOURCe OF 
MATeRiAL FOR DeveLOPMeNTAL 
ReSeARCH
The umbilical cord connects fetal circulation to the placenta 
providing nutrition and oxygen to the embryo while removing 
FiGURe 1 | Use of newborn stem/progenitor cells for assessment of individual and/or population-wide sensitivity to toxicants. Steps 1–4: a library of 
donor-specific cells can be used in a variety of high-throughput screening (HTS) assays depicted in Step 5. HTS assays provide information for either personal (lower 
left chart) or population-wide (lower right chart) toxicological assessment. Left chart shows dose-dependent inhibition of a cellular function (such as proliferation). 
Based on this curve, a chemical dose leading to 50% inhibition of a cellular function IC50 is determined. Right chart shows a hypothetical distribution of cellular 
responses (IC50) to a given toxicant. Dashed areas represent arbitrary thresholds for both most sensitive (left) and most resistant (right) phenotypes (individuals). 
HSCs, hematopoietic stem cells; MSCs, mesenchymal stem cells; EPCs, endothelial progenitor cells.
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metabolic waste. It consists of two arteries and one vein sur-
rounded by a mucoid connective tissue called Wharton’s jelly. Both 
Wharton’s jelly and the blood (cord blood) present a rich source 
of fetal material, including stem and progenitor cells (Figure 1) 
(22–27). The umbilical cord is a unique organ because it belongs 
to both fetus and newborn. Cord blood cells are formed during 
fetal development and harvested at birth. Fetal hematopoiesis 
presents a complex process that occurs in different anatomical 
locations, depending on the stage of gestational development (28, 
29). It appears that cord blood cells are generated through expan-
sion and maturation of hematopoietic stem cells (HSCs) from 
very early developmental stages. Essentially, cord blood presents 
a non-invasive source of fetal/newborn tissue.
Therapeutic potential of cell-based treatments have stimu-
lated intensive research efforts on how to isolate, expand, and 
preserve various cell types from cord blood. In particular, cord 
blood is a source of HSCs, which have considerable therapeutic 
value because of their blood-forming capacity and ability to 
re-populate bone marrow in patients affected by cancer or other 
blood and immune system disorders (30). Like other stem cells, 
HSCs slowly divide in vivo and hardly proliferate in vitro (31, 32). 
Currently, proliferation of HSCs ex vivo presents an area of very 
intense research effort in cord blood transplantation because a 
low number of proliferative blood-forming cells limit successful 
restoration of the recipient’s bone marrow (24, 33). The use of 
HSCs for other purposes, such as developmental research or epi-
demiological studies, is also limited waiting for the development of 
reliable methods of cell culture expansion and cryopreservation.
A variety of phenotypically distinct (non-hematopoietic) 
precursor cells, apart from HSCs, can be isolated from cord blood 
and/or Wharton’s jelly (22, 23). Some of these cells have consider-
able proliferation potential in vitro and, thus, can be employed 
for both therapeutics and developmental research. For example, 
mesenchymal stem (stromal) cells (MSCs) can be isolated from 
cord blood and produce highly proliferative cultures (34, 35). 
With an appropriate stimulation, MSCs differentiate into a vari-
ety of tissues, including bone, cartilage, fat, or muscle (34, 36–38). 
Importantly, MSCs lack immunogenic cell surface markers, 
which are critical, for the success of transplantation. Therefore, 
in vitro expanded and differentiated MSCs can be potentially very 
useful for regenerative medicine, for example, to improve heart 
function after myocardial infarction (39). However, the rate of 
MSCs isolation from cord blood is currently <50% (34, 35). This 
means that MSCs can be isolated from only a subset of newborns. 
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It remains unknown, what defines such selectively and whether it 
is important for transplantation purposes. Likewise, population-
wide studies involving MSCs, although on the horizon, do not 
seem feasible at the moment.
For population-wide research, endothelial progenitor cells (EPCs) 
represent a better choice. EPCs are easy to isolate, expand ex vivo, and 
cryopreserve. EPCs are circulating cells capable of proliferating and 
differentiating into mature endothelial cells (40, 41). Identification 
of putative circulating EPCs that are involved in postnatal vasculo-
genesis and vascular repair was reported in 1997 (42, 43). EPCs are 
characterized by expression of surface markers CD34 and VEGFR-2 
(KDR and CD309) and the ability to uptake acetylated-LDL and to 
bind Ulex lectin. Subsequent studies have revealed that true EPCs do 
not express the leukocyte common antigen CD45 and form colonies 
that appear after 2–3 weeks in culture producing long-term highly 
proliferative donor-specific lines (44, 45). These cells were named 
late outgrowth endothelial cells or endothelial colony-forming 
cells (ECFCs). Because of their involvement in neovascularization, 
ECFCs are being studied as a therapy for ischemic limb or heart 
disease and as an imaging probe for vasculogenesis (46). From our 
own experience, ECFCs isolated from cord blood are especially 
interesting for developmental studies because of the high success 
rate (~90%) of their isolation. We routinely isolate ECFCs from cord 
blood and use them to study individual responses to drugs, chemical 
toxicants, and other environmental hazards. Particularly, we have 
found that low doses of ionizing radiation affect their ability to pro-
liferate (47); the magnitude of the effect appears to be donor specific. 
The direct measurement of cell proliferation presents an example of 
how donor-specific cells can be used to rank individuals by cellular 
sensitivity to radiation; such ranking can hardly be inferred from the 
genomic, epigenomic, metabolomics, or transcriptional profile data. 
Using a similar approach, we received preliminary data indicating 
that the proliferation of ECFCs can be also inhibited by exposure to 
chemical toxicants, i.e., endocrine disruptor Bisphenol A and heavy 
metal cadmium.
In summary, cord blood cells represent a rich source of fetal/
newborn cells. The limiting factor in using HSCs and MSCs 
for studying individual variability of cellular responses lies in 
lack of the effective techniques allowing for their isolation and 
expansion in vitro. By contrast, such techniques exist for ECFCs. 
Theoretically, a collection of donor-specific ECFCs can serve as a 
model for assessing individual variability in response to toxicants, 
because ECFCs represent cells in circulation that are in direct 
contact with ingested/absorbed toxicants and their metabolites. 
Expansion of this approach to MSCs, other cell types differenti-
ated from MSCs, and HSCs can be realistic in the near future as 
the methodology for their isolation is rapidly developing.
CORD BLOOD CeLLS PReSeNT AN 
OPPORTUNiTY TO ADvANCe 
DeveLOPMeNTAL TOXiCOLOGY
As a potential platform for fetal toxicity testing, cord blood-derived 
MSCs, ECFCs, and other progenitor cells have several advantages. 
As noted above, these cells provide an opportunity to directly 
test how environmental toxicants affect the dynamics of cellular 
function and metabolism, arising from a complex interaction 
between genes, proteins, and cellular organelles. Donor-specific 
cells carry not only the entire genomic but also possibly the epi-
genomic information of a donor. We suggest that a collection of 
donor-specific cells can potentially capture a spectrum of human 
variability in response to a certain toxicant or a class of toxicants 
(Figure 1).
Unlike epidemiological focus on individual variability within the 
population, the traditional toxicology testing does not address this 
aspect of environmental interactions but aims to answer the ques-
tion of whether a specific agent is or is not toxic at a specific dose 
(48). The traditional toxicological testing minimizes variability of 
results by using a standardized test method that reduces the inherent 
variability of a biological model (e.g., using an inbred rodent strain). 
This contrast between standardization and the biological diversity 
of human populations has not been addressed. Extension of toxi-
cological testing to collections of human fetal/newborn cells may 
be essential in order to better understand the effect of toxicants on 
fetal development in human populations. Using cord blood-derived 
stem and progenitor cells can address the following questions:
 1. What is the lowest dose of a toxicant affecting human fetal 
cells? Is this dose different between cell types? Direct measure-
ments of donor-specific cellular responses allow researchers to 
determine the range of fetal/newborn variability in response 
to toxicants. ECFCs, MSCs, and other cord blood-derived 
cells can give rise to a variety of cell types, including mature 
endothelial cells, osteoblasts, adipocytes, chondrocytes, 
neural, muscle, and myocardial cells. Variability of responses 
between cell types will provide information on tissue target.
 2. Are fetal cells derived from cord blood more vulnerable to 
developmental toxicants as compared to human adult cells? 
To which degree are the results of cord blood cell testing con-
cordant with animal-based in vitro and in vivo models? These 
proposed comparisons extend the existing framework of 
embryotoxicity testing and may provide valuable information 
on similarities and differences of cellular responses derived 
from animals and humans.
 3. How similar are the cellular mechanisms responsible for 
toxicological effects in cord blood cells and animal in  vitro 
models? Although cellular mechanisms are assumed to be 
conserved, the difference in toxicity between embryonal and 
adult cells is widely acknowledged. Extending this logic to 
inter-species variability, confirmation of mechanistic similar-
ity in responses between embryonic mouse and human fetal 
cells provides additional in-depth validation of in vitro testing 
of developmental toxicants.
 4. Can fetal cells be used to evaluate the teratogenic potential 
of chemical toxicants? In comparison to the classical animal 
model evaluating teratogens, all cellular models, including 
cord blood cells, have obvious limitations. In vitro testing of 
cellular responses cannot be extrapolated to teratogenic effects 
directly. However, this model can be used as the first line 
screening to evaluate teratogenic potential in comparison with 
the effects of known teratogens with a similar chemical struc-
ture. This approach has been used in evaluating developmental 
neurotoxicity of organophosphorus flame retardants (49).
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These perspectives provide a focus for further discussions of 
the population-based approach in developmental toxicology. In 
the next section of this review, we discuss how this approach fits 
into the global shift within toxicology science.
DONOR-SPeCiFiC COLLeCTiONS OF 
PRiMARY CORD BLOOD CeLLS 
ADDReSS THe SHiFT iN TOXiCiTY 
TeSTiNG APPROACHeS: FOCUS ON 
HiGH-THROUGHPUT CAPACiTY AND 
BiOLOGiCAL MeCHANiSMS
The National Research Council’s Committee on Toxicity Testing 
and Assessment of Environmental Agents produced the report 
“Toxicity Testing in the 21st Century: A Vision and a Strategy” 
outlining the need for improvements in evaluating human risk 
posed by the thousands of chemicals in use (50, 51). A collabora-
tion known as Tox21 was formed including the National Institute 
of Environmental Health Sciences (NIEHS)/National Technology 
Program (NTP), the U.S. Environmental Protection Agency’s 
(EPA) National Center for Computational Toxicology (NCCT), 
the National Human Genome Research Institute (NHGRI)/
National Institutes of Health (NIH) Chemical Genomics Center 
(NCGC) [now located at the National Center for Advancing 
Translational Science (NCATS)], and the U.S. FDA (51, 52). 
Through the Tox21 program, toxicology is shifting from a pre-
dominately observational science at the level of disease-specific 
models in vivo to a predominantly predictive science focused on 
inclusion of target-specific, mechanism-based, and biological 
observations in vitro (52). Such shift to in vitro testing is justified 
by its higher capacity and lower cost compared with in vivo mod-
els and the potential for data more directly relevant to humans.
Next-Generation Toxicological Research 
Aims to implement High-Throughput and 
Population-wide Testing of Cellular 
Responses to Toxicological Agents
The EPA is required under the Toxic Substances Control Act 
(TSCA) to compile and publish a list of each chemical substance 
that is manufactured or processed in the U.S. that requires toxico-
logical testing (53–55). Exempt from TSCA are drugs, cosmetics, 
foods, food additives, pesticides, and nuclear materials, which are 
regulated by other agencies (53, 54). Approximately 500–1,000 
new substances are added to the TSCA inventory each year (53). 
Currently, there are over 84,000 chemicals in use with ~4,000 
chemicals produced in high production volume (above 1 million 
pounds annually) (53, 54, 56). The Tox21 program has compiled a 
compound library of >10,000 substances of toxicological interest, 
including pharmaceuticals (51).
Addressing this problem of inadequate toxicological data 
on a large number of chemicals, Tox21 proposed cell-based 
in vitro assays as the first screen test for prioritizing substances 
for further toxicological evaluation (56–58). Cell-based assays 
can process >100,000 compounds per day making this high-
throughput screening approach efficient in time and cost as 
well as allowing testing compounds at many concentrations 
(52, 57). The Tox21 program tests all compounds at typi-
cally 15 concentrations to generate concentration–response 
curves (51, 52). This dose–response-based method is highly 
reproducible generating significantly fewer false-positive and 
false-negative results as compared to the traditional approach 
used for drug discovery, which tests compounds at only one 
concentration (51, 52).
As articulated by Collins et  al. (52), the focus on human 
relevance requires in vitro testing of human cell lines. As noted 
above, an important element of human relevance is population 
variability in responses to toxicological agents (59, 60). The 
recently published study by Abdo et al. (59) presents an example 
and sets up the methodological stage for a transition toward 
population-based in vitro testing. This study assessed variation in 
cytotoxic response to 179 chemicals in 1,083 lymphoblastoid cell 
lines (peripheral B lymphocytes immortalized with Epstein–Barr 
virus). The cell lines represent nine populations from five con-
tinents, including individuals of European (USA, Great Britain, 
and Italy), Chinese (China), Japanese (Japan), African (Kenya 
and Nigeria), Mexican (Los Angeles, CA, USA), and Colombian 
(Colombia) ancestries.
Abdo et al. (59) used EC10 (10th percentile; concentration for 
which cell viability was 90%) as the lowest concentration induc-
ing a significant effect on cell growth. The variability of EC10 
values across the cell lines was several orders of magnitude for the 
majority of chemicals. These results unequivocally demonstrate 
that individual variability in human responses to environmental 
toxicants cannot be ignored in risk assessment. Toxicological 
testing using human material (i.e., in  vitro cell-based testing) 
represents the only option to assess such variability.
This study by Abdo et  al. is remarkable in several ways. 
Lymphoblastoid cell lines have been criticized as a model, 
because these are transformed cells and because they represent 
only one highly specialized cell type. How can the results of such 
testing be extrapolated to other cell types and more importantly 
to humans in  vivo? Despite these limitations, the study by 
Abdo et  al. validated the concept that a cell can represent an 
individual at least to some degree. First, it demonstrated that 
inter-individual variability of the in vitro results is comparable 
to in vivo human toxicodynamic variability. Second, the study 
connected phenotypic biochemical testing with genetic vari-
ability, thereby setting up the example of how in vitro testing can 
be used for genome-wide association studies of human genetic 
susceptibility to chemicals. Specifically, the diversity in cellular 
responses was mapped to the genes with proteins that are local-
ized to cell membranes, including solute carriers, which have 
been identified as potential mediators of antineoplastic drugs’ 
cytotoxicity (61, 62). Thus, the results derived from this testing 
of highly specialized (and immortalized) cells do inform on the 
general variability of individual response to a toxicological agent. 
As direct in vivo validation of human in vitro testing is impos-
sible, these results set up examples of indirect validation using 
the existing human data.
Primary cell lines from cord blood cells fit ideally into this 
conceptual framework. We and others demonstrated that ECFCs 
have high proliferation potential in vitro and, thus, are suitable 
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for high-throughput assays (47, 63, 64). As lymphoblastoid cell 
lines represent to a considerable extent the biological individual-
ity of the donors, it is logical to expect that biobanks of primary 
ECFC cell lines from cord blood could represent populations of 
newborns. In addition, there is an advantage of using primary 
as opposed to transformed cell lines as primary cells provide an 
opportunity to test important cellular targets of developmental 
toxicology, such as cellular growth and differentiation. Taking 
into account that human fetuses and newborns represent vulner-
able populations with respect to environmental toxicants such 
in vitro testing of cord blood cells may uncover a different range 
of EC10 as compared to adult cells.
Focus on Mechanism-Based Biological 
Observations In Vitro
Focus on functional mechanism-based assays can be illustrated by 
high-throughput testing of mitochondrial function. Mitochondria 
have been recognized as a sensitive target for environmental com-
pounds, because these organelles play a central role in cellular 
responses to environmental stressors (65). NCATS conducted the 
first high-throughput screening of a large number of chemicals to 
assess their effect on mitochondrial function. Attene-Ramos et al. 
assessed 1,340 unique environmental and drug-like compounds 
for their ability to change mitochondrial membrane potential in 
human hepatocellular carcinoma cells (HepG2) (58).
This approach identified 255 (~20%) compounds that 
decreased mitochondrial membrane potential in a concentra-
tion-dependent manner (58). Furthermore, the second round 
confirmatory testing used a different readout and showed a 
high concordance rate of >90% with the first line screening 
(58). In addition, seven of the inactive analogs were reevalu-
ated with all confirming their inactive status (58). Compounds 
were further assessed for mechanism of action by measuring 
changes in oxygen consumption rate; this testing identified 20 
compounds as uncouplers (inhibitors of the ATP synthesis via 
dissipation of membrane potential) (58). This comprehensive 
approach using primary quantitative high-throughput screen-
ing assays with in-depth secondary screening is an example 
of studying the mechanism of action (58). This test method 
was subsequently used to screen the Tox21 10,000 compound 
library (66).
Extension of this approach to primary cell lines isolated from 
cord blood may bring an unprecedented rate of discoveries that 
will help to reveal how exactly environmental toxicants influence 
early human development. A continuum of data delineating-
specific biological mechanisms can connect developmental 
toxicology to human populations.
CONCLUSiON
Cord blood cells have been used for therapeutic purposes. At the 
same time, cord blood presents a non-invasive source of human 
fetal cells. Cord blood stem and progenitor cells can be isolated, 
expanded in vitro, and cryopreserved. Current techniques, which 
are rapidly expanding, allow for the isolation and expansion 
in vitro of ECFCs and MSCs. Whereas ECFCs can be easily iso-
lated from cord blood, MSCs are currently isolated from ~50% of 
the specimens. Thus, the population-based approach is feasible 
currently only with ECFCs.
As the principles of toxicological testing are shifting toward the 
use of more in vitro models, a testing platform based on primary 
fetal cell lines derived from cord blood fits well into this research 
paradigm. Importantly, it has been demonstrated that human 
cell lines representing different individuals could capture a wide 
variability of individual responses to a tested toxicant. Similarly, 
a collection of primary cord blood-derived cell lines can inform 
developmental toxicology about the variability of fetal/newborn 
responses to a toxicant. As with any model, use of cord blood cells 
as a proxy of a human fetus/newborn has its limitations. In vitro 
testing of cellular responses cannot be directly extrapolated to 
many teratogenic effects, such as malformations or childhood 
obesity. However, this model can be used to evaluate a teratogenic 
potential in comparison with the effects of known teratogens of 
a similar chemical structure. With this review, we would like to 
open a discussion of the exciting opportunities of using cord 
blood stem and progenitor cells as a window into in utero and 
early postnatal development.
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